Epizyme Announces Date of Third Quarter 2017 Financial Results
25 oct. 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Closing of Public Offering of Common Stock
19 sept. 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the closing of its...
Epizyme Announces Pricing of Public Offering of Common Stock
14 sept. 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the pricing of an...
Epizyme Announces Proposed Public Offering of Common Stock
13 sept. 2017 16h01 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it intends to...
Epizyme to Participate in Upcoming Investor Conferences
30 août 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Leadership Transition for Finance Organization
15 août 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership...
Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
04 août 2017 06h30 HE
|
Epizyme, Inc.
Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors Expansion of Collaborations to Accelerate Investigation of Tazemetostat Across Multiple...
US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
01 août 2017 06h30 HE
|
Epizyme, Inc.
THE WOODLANDS, Texas and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US...
Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
31 juil. 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
24 juil. 2017 16h05 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the National...